Gilead Sciences, Inc. has entered into a definitive agreement to acquire Immunomedics for approximately $21 billion in cash, which was approved by both the Gilead and Immunomedics Boards and is anticipated to close during 4Q20. The acquisition provides Gilead with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. FDA in April for the treatment of metastatic triple-negative breast cancer (mTNBC...